HOME > Detail View

Detail View

mTOR inhibition for cancer therapy [electronic resource] : past, present and future

mTOR inhibition for cancer therapy [electronic resource] : past, present and future

Material type
E-Book(소장)
Personal Author
Mita, Monica. Mita, Alain. Rowinsky, Eric K.
Title Statement
mTOR inhibition for cancer therapy [electronic resource] : past, present and future / edited by Monica Mita, Alain Mita, Eric K. Rowinsky.
Publication, Distribution, etc
Paris :   Springer Paris :   Imprint: Springer,   2016.  
Physical Medium
1 online resource (vi, 300 p.) : ill. (some col.).
ISBN
9782817804927
요약
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
General Note
Title from e-Book title page.  
Content Notes
Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
Bibliography, Etc. Note
Includes bibliographical references and index.
이용가능한 다른형태자료
Issued also as a book.  
Short cut
URL
000 00000nam u2200205 a 4500
001 000046019018
005 20200305111134
006 m d
007 cr
008 200228s2016 fr a ob 001 0 eng d
020 ▼a 9782817804927
040 ▼a 211009 ▼c 211009 ▼d 211009
082 0 4 ▼a 616.994061 ▼2 23
084 ▼a 616.994061 ▼2 DDCK
090 ▼a 616.994061
245 0 0 ▼a mTOR inhibition for cancer therapy ▼h [electronic resource] : ▼b past, present and future / ▼c edited by Monica Mita, Alain Mita, Eric K. Rowinsky.
260 ▼a Paris : ▼b Springer Paris : ▼b Imprint: Springer, ▼c 2016.
300 ▼a 1 online resource (vi, 300 p.) : ▼b ill. (some col.).
500 ▼a Title from e-Book title page.
504 ▼a Includes bibliographical references and index.
505 0 ▼a Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
520 ▼a This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
530 ▼a Issued also as a book.
538 ▼a Mode of access: World Wide Web.
700 1 ▼a Mita, Monica.
700 1 ▼a Mita, Alain.
700 1 ▼a Rowinsky, Eric K.
856 4 0 ▼u https://oca.korea.ac.kr/link.n2s?url=http://dx.doi.org/10.1007/978-2-8178-0492-7
945 ▼a KLPA
991 ▼a E-Book(소장)

Holdings Information

No. Location Call Number Accession No. Availability Due Date Make a Reservation Service
No. 1 Location Main Library/e-Book Collection/ Call Number CR 616.994061 Accession No. E14019800 Availability Loan can not(reference room) Due Date Make a Reservation Service M

New Arrivals Books in Related Fields

대한심장학회. 여성심장질환연구회 (2020)
대한심장학회. 심인성쇼크연구회 (2021)
대한소화기내시경학회. 캡슐인공지능영상연구회 (2021)
정종영 (2020)